

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/829,467	04/09/2001	Hiroshi Shinoki	JG-SIK-5063/500676.20003	8683
7590 12/13/2005			EXAMINER	
Jules E. Goldberg			FREDMAN, JEFFREY NORMAN	
REED SMITH LLP 599 Lexington Avenue 29th Floor			ART UNIT	PAPER NUMBER
New York, NY 10022			1637	

DATE MAILED: 12/13/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/829,467	SHINOKI ET AL.				
Office Action Summary	Examiner	Art Unit				
-	Jeffrey Fredman	1637				
The MAILING DATE of this communication						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR RE THE MAILING DATE OF THIS COMMUNICATIO - Extensions of time may be available under the provisions of 37 CFI after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory pe - Failure to reply within the set or extended period for reply will, by st Any reply received by the Office later than three months after the m earned patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a reply reply within the statutory minimum of thirty (3 riod will apply and will expire SIX (6) MONTH atute, cause the application to become ABAN	y be timely filed 30) days will be considered timely. S from the mailing date of this communication. IDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 2	3 September 2005.					
,—						
<i>,</i>						
Disposition of Claims						
4)⊠ Claim(s) <u>1,3,7,11,13,15,17,19,27,32 and 33</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
· ·	(i) ☐ Claim(s) is/are allowed. (ii) ☐ Claim(s) <u>1,3,7,11,13,15,17,19,27,32 and 33</u> is/are rejected.					
· <u> </u>						
7) Claim(s) is/are objected to.						
· _ · · · · · · · · · · · · · · · · · ·						
Application Papers						
9) The specification is objected to by the Exam	niner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the	Examiner. Note the attached C	Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for fore	eign priority under 35 U.S.C. § 1	19(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority docum	ents have been received in App	lication No				
3. Copies of the certified copies of the p	priority documents have been re	ceived in this National Stage				
application from the International Bur	reau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a	list of the certified copies not rec	ceived.				
Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
1) ⊠ Notice of References Cited (PTO-892) 2) ☑ Notice of Draftsperson's Patent Drawing Review (PTO-948)		nmary (PTO-413) fail Date				
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB. Paper No(s)/Mail Date 		mal Patent Application (PTO-152)				

DETAILED ACTION

Claim Rejections - 35 USC § 112

1. Claim 11 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 11 lacks antecedent basis for R1 and R2 since claim 3 does not refer to any R groups whatsoever. Claim 11, in consequence, cannot be further examined since it makes no sense since there is no antecedent basis for the "wherein at least one of R1 and R2 is an alkyl group substituted with a carboxyl group".

Claim Interpretation

2. In interpreting claim 1, the claim uses very permissive language. Specifically, Claim 1 states that "C represents a monovalent group derived from a fluorescent dye". So claim 1 does not require that C is a dye, only that C is a monovalent group derived from a dye. The only other positive requirement for element C is that it have a "sulfonamide group". There is no requirement that C itself be a fluorescent dye or function as a fluorescent dye in any way. The following rejection utilizes this broad interpretation of element C.

So when the claims use the "derivative" language, this permits any subpart to be called a "derivative". The term is not defined in the specification and therefore the broadest reasonable interpretation is applied.

Application/Control Number: 09/829,467

Art Unit: 1637

Claim Rejections - 35 USC § 102

Page 3

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 1, 3, 7, 13, 15, 17, 19, 27, 32 and 33 are rejected under 35 U.S.C. 102(b) as being anticipated by Frame et al (Tetrahedron (1996) 52:9219-9236).

Frame teaches a nucleotide of claims 1 and 27, at page 9220, as shown below:

The structure of Frame the element A, a nucleotide, linked by an element B, a divalent linking group to an element C, which has a monovalent group, specifically H or CH₂ and which has a sulfonamide group.

With regard to claim 3, 7, 13, 32 and 33 the cyanine dyes comprise both H and or CH₂ groups and there is a H and CH₂ group in the Frame nucleotide.

With regard to claim 15, Frame teaches adenosine nucleotides and "derivatives thereof" (see page 9220).

Application/Control Number: 09/829,467

Art Unit: 1637

With regard to claims 17, 19, Frame teaches the sulfonamide is linked to the derivative of the nucleotide by a CH=CH bond (since claim 1 does not require a complete nucleotide by use of the "derivative" language, the derivative can be the sugar ring which is linked to the base. This makes the base the "B" linking group, and the base in Frame comprises, for example, a CH=CH bond or amino allyl group).

This situation is similar to the situation that the Federal Circuit discussed in In re Morris, where the Federal Circuit noted "Absent an express definition in their specification, the fact that appellants can point to definitions or usages that conform to their interpretation does not make the PTO's definition unreasonable when the PTO can point to other sources that support its interpretation." In re Morris, 44 USPQ2d 1023, 1029 (Fed. Cir. 1997). In the current case, the term "derivative" renders the claim extremely broad, since even a single hydrogen or carbon are "derivatives" of nucleotides or cyanine dyes. The decision of the court in In re Bigio, 72 USPQ2d 1209 (Fed. Cir. 2004) strongly supports the breadth of interpretation. That court notes "Nevertheless, this court counsels the PTO to avoid the temptation to limit broad claim terms solely on the basis of specification passages." This caselaw supports a broad interpretation of the term "derivative".

Response to Arguments

5. Applicant's arguments filed September 23, 2005 have been fully considered but they are most in view of the new grounds of rejection.

As a side note, the Caputo patent teaches overlapping Markush groups with the current claims, which are rejected under 102 (b), but Caputo does not predate the

Japanese priority documents which provide structures which fall within the scope of the claims and provide support for the claims.

Conclusion

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/829,467 Page 6

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jeffrey Fredman Primary Examiner Art Unit 1637